Most material SEC filings — July 9, 2026

Whitestone REIT shareholders approved the all-cash acquisition by Ares Real Estate funds on July 9, 2026. The purchase price is $19.00 per share or unit, valuing the transaction at approximately $1.7 billion. Closing is expected July 14, 2026, subject to customary conditions.

As of July 8, 2026, Eightco Holdings (market cap ~$3.8M) disclosed total treasury holdings of approximately $397 million, comprising: $90 million indirect equity in OpenAI (through SPVs), 283.5 million Worldcoin (WLD) tokens valued at $0.39/token (~$110M), 16,278 ETH, $18 million in Beast Industries equity, $1 million in Mythical Games, and $149 million cash/stablecoins. The company holds 8.1% of circulating WLD supply—the largest publicly disclosed institutional position globally. No material changes in holdings were announced; this is a portfolio composition disclosure dated July 8, 2026.

IKS Health announced completion of its acquisition of TruBridge, Inc. on July 9, 2026. TruBridge, a provider of EHR and revenue cycle management solutions for rural and community hospitals, now operates as a wholly owned subsidiary of IKS Health. The combined organization serves over 2,000 healthcare organizations and 150,000 clinicians. Specific acquisition price, share count, and percentage ownership details are not disclosed in this filing.

Hydrofarm Holdings Group received a Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard on July 2, 2026. The filing indicates the company has failed to meet exchange listing requirements, though specific details regarding which standard(s) were violated and any remediation timeline are not disclosed in this 8-K excerpt. With a public market value of ~$16.0M, delisting represents an existential threat to the company's ability to raise capital and operate as a public entity.

On July 2, 2026, Onfolio Holdings, Inc. (public market value ~$4.2M) received notice of delisting or failure to satisfy continued listing standards. The filing indicates Item 3.01 notification regarding delisting risk or listing transfer. No specific financial figures, counterparties, or remediation details are disclosed in this filing excerpt.

On July 2, 2026, Bayview Acquisition Corp received notice of delisting or failure to satisfy continued listing rules/standards from its exchange (Item 3.01). The filing provides no specific details on remediation timeline, listing standard violated, or transfer procedures. This is a critical governance event for a $39.4M market-cap blank-check company.

Netcapital Inc. (market cap ~$2.9M) entered into an equity purchase agreement with Hudson Global Ventures, LLC on June 29, 2026, establishing a $15,000,000 maximum commitment for the investor to purchase put shares at prices calculated from market prices. Simultaneously, Netcapital issued Hudson Global a warrant to purchase 1,000,000 shares at $0.50/share, exercisable from June 29, 2026 to June 29, 2029. The deal includes registration rights and detailed mechanics for share delivery, with Hudson Global able to execute cashless exercises and subject to a 4.99% beneficial ownership cap.

Air Industries Group (AIR, ~$10M market cap) is merging with Tenax Aerospace Acquisition LLC in a stock-for-stock transaction. AIR will issue 126,900,000 shares (25,380,000 post-reverse split) to Tenax members as merger consideration. The amended merger agreement, dated July 2, 2026, supersedes prior versions and includes a 5-for-1 reverse stock split of AIR shares. Tenax is an aerospace company; financial details show Tenax 9M 2025 revenues and AIR's recent fiscal metrics are disclosed but specific combined valuations/synergies are not stated in this excerpt.

Prairie Operating Co. (market cap ~$74.1M) received notice of delisting failure on July 2, 2026, reported via 8-K filed July 9, 2026. The filing invokes Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard) and mentions transfer of listing, but the specific rule violated, remediation timeline, and exact listing destination are not detailed in this document excerpt.

Interactive Strength Inc. (Buyer) is acquiring STEPR, Inc. (Company) from STEPR PTY LTD (Seller) and indirect equityholders (TF Trust, Australian Fitness Supplies) for: (1) F1 Equity Consideration of $6M in Series F-1 Preferred Stock; (2) F2 Equity Consideration of $10.5M in Series F-2 Preferred Stock; (3) F3 Equity Consideration of $2.5M in Series F-3 Preferred Stock; plus (4) Initial Cash Contribution of $1.5M (less Secured Note advances); (5) AFS Loan Repayment up to $1.2M; and (6) Shareholder Cash Consideration up to $1M on first anniversary. All equity consideration is non-voting convertible preferred stock subject to scaling factors tied to Year 1 and Year 2 EBITDA performance (capped at $4M and $7M respectively). Locked-box date: May 31, 2026. Agreement dated July 7, 2026.

Digital Brands Group announced its AVO brand partnered with the largest U.S. college bookstore chain (1,000+ locations) and will take over Lululemon's retail space across all bookstores. For Q3 2026, DBGI forecasts $8.5–$11M revenue (300–500% YoY growth) with break-even or positive net income, shifting from $3.5M loss in Q3 2025. Additional Q4 potential includes $8–$9M revenue and $3M+ net income from seven cities under a government contract, though delayed by government shutdown.

On June 15, 2026, Simulations Plus entered into a definitive merger agreement to be acquired by affiliates of Altaris, LLC, with closing expected in Q4 calendar 2026. Q3 FY2026 (ended May 31, 2026) revenue grew 7% to $21.9M ($20.4M prior year); software revenue flat at $12.6M; services revenue +20% to $9.3M. Net income $3.6M vs. prior-year loss of $67.3M (which included $77.2M impairment); adjusted EBITDA $7.9M (36% margin). Nine-month revenue +5% to $64.6M; net income $8.8M vs. loss of $64.0M.

On July 6, 2026, XWELL Inc. agreed to sell 100% of XpresSpa Holdings LLC and XpresTest Inc. to Express Wellness Group LLC for a base purchase price of $13,000,000, subject to working capital and other adjustments. The buyer is obligated by a limited guaranty from Face Haus LLC. Closing is subject to stockholder approval and customary conditions; the deal contemplates $2.65M in escrow accounts (adjustment, indemnity, and Atlanta-related).

On July 6, 2026, T3 Defense Inc. acquired a 60% equity stake in Project 35 Ltd. (an Israeli corporation developing FPV loitering munitions and interceptor technology) from X S.A. Security and Defense Ltd. for 21,059,871 shares of T3 common stock (capped at 19.9% of voting shares) plus a $1.25M promissory note at 12% interest due July 5, 2027. T3 committed to invest $2.5M into Project 35's treasury over 12 months for product development and launch.

Nurix entered a global co-development and co-commercialization agreement with Roche for bexobrutideg (BTK degrader) on July 9, 2026. Nurix receives $700M upfront within 30 days of closing, plus development/regulatory/commercial milestones totaling up to $2.3B inclusive. Nurix bears 40% of development costs, shares U.S. profits equally, and receives tiered ex-U.S. royalties. Agreement covers malignant hematology, immunology, and neurology; closing subject to Hart-Scott-Rodino antitrust clearance.

10% owner Globalharvest Holdings Venture Ltd (AVO) bought 1.2M shares (~$15.8M) on the open market (8.7% of holdings). Open-market insider purchase — historically a bullish signal.

Annovis Bio announced full enrollment of 850 patients (exceeding original projections) in its pivotal Phase 3 trial of buntanetap for early Alzheimer's disease across 83 US clinical sites. The trial has two pre-specified readouts: 6-month symptomatic data in Q1 2027 and 18-month disease-modifying data in Q1 2028, each intended to support separate NDA submissions to the FDA. This milestone positions the company to advance toward regulatory submissions for what could be its first marketed drug.

GridAI Technologies (market cap ~$14.9M) completed three private placements in May-July 2026 generating ~$16.3M gross proceeds ($4M received at close; $12.3M conditional on registration effectiveness). Company issued 9.9M common shares/warrants to investors including North York LTD and Strategic EP LLC. With only $386K cash (March 2026), accumulated deficit of $212.1M, and auditor going-concern warnings, the company states it has 18 months' liquidity assuming full funding and no unexpected costs. Grid AI subsidiary (acquired Sept 2025) targets AI data center power optimization; legacy Adrulipase program paused pending Phase 3 capital.

Simply Good Foods reported Q3 FY2026 net loss of $52.0M (vs. $41.1M income YoY) on net sales of $357.0M, down 6.3% YoY, driven by Atkins brand decline of 24.6%. Company recognized $82M impairment charge in Q3 ($331M YTD). Full-year FY2026 guidance cut: net sales expected $1.345–$1.355B (down 7–6% YoY), Adjusted EBITDA $220–$225M (down 21–19% YoY), and gross margins declining ~375 basis points. Q3 Adjusted EBITDA fell 22.5% to $57.2M. Debt increased to $400M as of May 30, 2026 after $150M borrowing in November 2025; Net Debt/Adj. EBITDA ratio 1.2x.

Forte's FB102 (anti-CD122 monoclonal antibody) achieved 29.6% mean FVASI improvement from baseline at week 24 versus 7.9% for placebo (p=0.020) in a 43-subject double-blind Phase 1b vitiligo study (32 FB102, 11 placebo). In the more severely affected subgroup (baseline FVASI ≥0.75), FB102 showed 43.2% mean improvement (p=0.006) with 58.8% achieving FVASI50 responder status. Statistical significance was reached by day 64 and persisted through week 24 post-treatment; 84% of treated subjects improved with 0% worsening, versus 27% of placebo subjects worsening. Safety profile remained mild-to-moderate with no severe adverse events.

MARA Holdings signed a definitive agreement to acquire a 1,200-acre digital infrastructure site in Matagorda County, Texas from HIF USA LLC. The site will provide up to 1 GW of grid capacity by October 2027 and 2 GW by April 2028. HIF retains minority ownership upon execution of an HPC tenant lease. Upon full energization, including the previously announced Long Ridge Energy Power acquisition, MARA's total capacity reaches ~4.8 GW (doubling current portfolio). Phased construction begins 2026; thousands of jobs expected.

Byrna Technologies reported Q2 2026 revenue of $16.4M vs. $28.5M YoY (−43%), driven by weak e-commerce and slower dealer/retail reorders. The company took $10.4M in non-cash charges: $5.9M inventory write-down (ammunition facility shutdown) and $3.5M equipment impairment. It also announced a binding agreement to acquire HERO Defense Systems and initiated cost-reduction actions (cut launcher assembly from 4 to 2 production lines, exited in-house ammunition manufacturing). Cash declined to $10.4M from $15.5M; adjusted EBITDA turned negative at $(0.6)M vs. $4.3M prior year. Management flagged fiscal 2026 will not be a growth year.

Element Solutions Inc agreed to merge with Solstice Advanced Materials Inc (Parent) in a two-step transaction dated July 6, 2026. Each Element Solutions share converts to 0.500 Parent shares plus $10.00 cash. As of July 1, 2026, Element Solutions had 243.7M shares outstanding; Parent had 158.8M shares outstanding. The transaction contemplates Parent issuing shares for the merger consideration and Parent obtaining debt financing. Designated Company directors will join Parent's board post-closing.

Solstice Advanced Materials Inc. (Parent) agreed to acquire Element Solutions Inc. (Company) via merger as of July 6, 2026. Element shareholders receive 0.50 Solstice shares plus $10.00 cash per share. Solstice will issue approximately 121.8M new shares (243.7M Company shares × 0.50 Exchange Ratio). Deal requires majority votes from both companies' shareholders and regulatory approvals; expected to close in H2 2026.

MetaVia announced July 9, 2026 that all enrolled patients in Phase 1 Part 3 of DA-1726 (dual GLP-1/glucagon agonist) successfully reached target doses of 48 mg (Part 3A, ~20 patients) and 64 mg (Part 3B, ~20 patients) across two 16-week titration cohorts. Topline data expected Q4 2026. Prior Phase 1 MAD data showed 9.1% mean weight loss at 48 mg in 8 weeks with improved waist circumference and glycemic measures.

Splash Beverage Group announced on July 8, 2026 that NYSE American accepted its compliance plan and granted a compliance period through January 29, 2027, after the company submitted the plan on May 29, 2026. The company stated it has secured an equity line facility for liquidity, completed a strategic investment in Avicanna, and acquired exclusive worldwide licensing rights to CannEpil. The filing does not specify dollar amounts for the equity facility, the Avicanna investment, or the CannEpil acquisition price.

Nixxy appointed David Kratochvil as Chief Executive Officer and President effective July 9, 2026 under a 12-month agreement. Compensation: $180,000 annual base salary plus 100,000 Stock Units vesting over 12 months (50,000 immediate, 12,500 at 3/6/9/12 months). Severance: 1 month base salary if terminated without cause after 90 days; 4 months if terminated without cause following a Change of Control. Agreement includes standard non-compete, confidentiality, and arbitration provisions.

Ionis and AstraZeneca announced that eplontersen failed to meet the primary efficacy endpoint in the CARDIO-TTRansform Phase 3 trial (1,432 patients across 130 sites in 20 countries) for treating transthyretin-mediated amyloid cardiomyopathy. The composite outcome of cardiovascular mortality and recurrent CV events was not statistically significant versus placebo in the overall population; however, a prespecified subgroup of eplontersen monotherapy patients showed a nominally significant hazard ratio of 0.71. The drug demonstrated a favorable safety profile and large TTR reductions, but 81% of patients were on or initiated stabilizer therapy during the trial, which the company cites as explaining the negative result.

Educational Development Corporation reported fiscal 2027 Q1 (ended May 31, 2026) net revenues of $4.8M versus $7.1M prior year, a 33% decline. Net loss widened to $1.4M from $1.1M; loss per share increased to $(0.16) from $(0.13). Active Brand Partners recovered to 5,300 from a low of 4,300, and cash improved to $1.8M from $1.3M. Management implemented a $1.2M annual cost reduction plan and wrote down $0.1M in assets held for sale (legacy distribution system).

Traws Pharma, Inc. filed a First Amendment to its 2021 Incentive Compensation Plan effective November 21, 2025, increasing reserved shares for grants by 2,000,000 shares (from ~1.5M to 3.5M total authorized shares). The amendment also adds flexibility for the Committee to reduce awards or extend vesting if a participant's employment status changes from full-time to part-time/contractor, and sets a $300,000 annual limit on Non-Employee Director compensation. All changes are contingent on stockholder approval at the 2026 Annual Meeting.

Renesas Electronics Corporation and its U.S. subsidiary (Renesas Electronics America Inc.) jointly filed a Schedule 13D on July 9, 2026, indicating a reportable stake acquisition in SiTime Corp. The filing discloses officers and directors of both Renesas entities but does not specify the stake percentage, share count, purchase price, or transaction details in the excerpts provided. This indicates Renesas has crossed a disclosure threshold (typically 5%+ ownership) and may signal strategic intent toward SiTime.

On July 6, 2026, Middleby completed the separation of its food processing business into Midera Food Processing, Inc., a new publicly traded company (ticker: MFP), by distributing 100% of Midera shares to Middleby shareholders on a 1:1 basis. Post-spin-off, Middleby received a $233M cash distribution from Alkar Holdings (Midera's subsidiary) funded by Midera debt, which Middleby will use to repay long-term debt. The spin-off reduces Middleby's pro forma Q1 2026 net sales by 27% (from $839.9M to $616.9M) and net earnings by 17% (from $85.3M to $70.7M), with Midera representing approximately $850M of Middleby's prior-year annual sales.

CleanCore Solutions (ZONE Member, 99% capital interest) and HST Technologies/Platform Co (1% capital interest) formed a Delaware LLC on July 2, 2026, to develop AI data center projects. ZONE commits $2B capital over 9 months initial + through 2029; Platform Co contributes project assets and technology (Cue platform). Platform Co receives 20% carried participation in promote economics after 12% preferred return to ZONE, plus up to $40M equity consideration ($60k–$80k per MW delivered capacity), $75k/month development fees, and MPA fees. Closing conditions include board approval, financing, and consents. Platform Co may pursue replacement financing if ZONE defaults, diluting ZONE's stake 1% per $200M raised.

Bush Associates CPA LLC, the departing independent auditor, confirmed in a July 7, 2026 letter that there were no disagreements with BIO-key International on accounting principles, practices, disclosure, or auditing scope during fiscal years 2024–2025 and through July 2026. Critically, the auditor's reports on both fiscal years included an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern—a material red flag for a $4.9M market-cap firm.

On October 15, 2025, James G. Silk converted $4,577,326 of Preferred Series A Subclass 1 Unit Accounts into Class A Common Stock at a conversion price of $0.52 per share (minimum price $840 waived). Concurrently, Hicks Holdings Operating, LLC converted $92,485,639 of the same preferred units. Both parties signed voting and lock-up agreements restricting share transfers until October 1, 2028, with share forfeiture provisions if stock price rises by January 1, 2028.

Bellevue Capital Partners, LLC purchased 18,000 shares of Class A Common Stock between June 15 and June 30, 2026, via open market transactions at prices ranging from $7.71 to $9.85 per share, totaling approximately $161,000. The largest single purchase occurred on June 30, 2026 (8,000 shares at $9.53/share weighted average). This acquisition triggers Schedule 13D/A reporting requirements for significant shareholder activity.

Stereotaxis completed its acquisition of Robocath, a France-based developer of robotic solutions for interventional cardiology and neurointerventions, as of July 9, 2026. The filing does not disclose the purchase price, share count exchanged, or other financial terms. Robocath's R-One robotic platform has CE and NMPA certifications and is currently deployed in Europe and China; the combined entity aims to expand robotic offerings across electrophysiology, interventional cardiology, and neurointerventions.

Ampco-Pittsburgh announced customer order activity of $268 million for H1 2026, up 32% from $204 million in H1 2025. FCEP segment orders grew 25% to $153 million; Air and Liquid Processing grew 42% to $116 million. Growth driven by roll products in North America, Navy pump programs, and Buffalo Air Handling's largest-ever order.

enCore Energy Corp. terminated CEO Robert J. Willette without cause effective April 20, 2026 (separation date July 8, 2026). The company paid $1.8 million in cash severance (less taxes and documented attorney fees) and granted 300,000 fully vested nonqualified stock options with a 5-year exercise term at the July 16, 2026 closing price, in exchange for a general release of all claims and continued restrictive covenants (confidentiality, non-disparagement, non-solicitation). All unvested equity was forfeited; vested options expire 90 days post-separation. Willette also committed to cooperate with two pending litigation matters.

10% owner Aqua Capital, Ltd. (ENR) bought 80K shares (~$1.6M) on the open market (1.1% of holdings). Open-market insider purchase — historically a bullish signal.

Director Moret Silvestre Vila (GGAL) bought 403K shares (~$2.1M) on the open market (13% of holdings). Open-market insider purchase — historically a bullish signal.

WD-40 reported Q3 2026 (ended May 31) net sales of $195.1M (+24% YoY; +20% constant currency), with operating income of $40.3M (+47%) and diluted EPS of $2.24 (+45%). All three geographic segments showed double-digit growth: Americas +29%, EIMEA +17%, Asia-Pacific +24%. Management reclassified Americas homecare/cleaning brands from held-for-sale to held-for-use, adding ~$12M sales and $0.17 EPS to FY2026 guidance. Updated FY2026 guidance: $675–$690M sales (+10–12%), $107–$113M operating income (+5–11%), $6.05–$6.35 diluted EPS (+6–11%). Board approved new $100M share repurchase program effective Sept 1, 2026; Q3 repurchased 31,250 shares for $6.8M.

Globalharvest Holdings Venture Ltd. purchased 1,829,502 shares of Mission Produce common stock over three days in early July 2026 at prices ranging from $12.73–$13.42/share, totaling approximately $24.6M. This represents a 13D/A amendment disclosing open-market accumulation by a significant shareholder.

On March 19, 2026, Prestige Consumer Healthcare entered into an asset purchase agreement to acquire the OTC Wellness Business from Foundation Consumer Brands LLC (FCB), comprising brands: Breathe Right, Dimetapp, Anbesol, Alavert, Primatene, Dristan, FiberCon, Campho-Phenique, St. Joe's Low Dose Aspirin, and Bronkaid. Q1 2026 pro forma financials for the acquired business show net sales of $51.7M (vs. $50.5M prior year) and net income of $12.6M (vs. $14.8M prior year), with intangible assets and goodwill totaling $479.8M. Transaction completion date and purchase price not disclosed in this filing excerpt.